UBS analyst Andrew Ang reiterated a Neutral rating and $300.00 price target on BioNTech (NASDAQ: BNTX) after the WHO declared ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE